Versameb AG
Versameb AG is a clinical-stage biotechnology company pioneering RNA-based therapeutics to address unmet medical needs. Its proprietary VERSagile platform optimizes RNA functionality for enhanced therapeutic potential. Lead candidate VMB-100, a novel mRNA therapy for stress urinary incontinence (SUI), is advancing to Phase 2a trials in 2025. Based in Basel, Versameb is committed to transforming medicine through innovative RNA science.
Date, time and room information
May 5, 15:00 - 15:15, room Montreal
Category
Clinical stage development company
Title of the presentation
Transforming RNA therapeutics
Speaker information
| Name | Position | Institution |
|---|---|---|
| Klaas Zuideveld | CEO | Versameb AG |
